Why the study?
Does DNA-complexed adriamycin alter pharmacokinetics compared to free adriamycin in children with malignant disease?
Does DNA-complexed adriamycin alter pharmacokinetics compared to free adriamycin in children with malignant disease?
DNA-complexed adriamycin significantly alters the pharmacokinetic profile in children with malignancies, leading to higher plasma levels and reduced urinary excretion.
Answers are grounded in this paper and cite their sources.
May warrant caution with DNA-complexed adriamycin in children; leaves open therapeutic implications pending controlled trials.
The pharmacokinetics of adriamycin given as free and in DNA-complexed form was compared in six children with malignant disease. The two types of adriamycin were given to the same child at 3--4-week intervals, thereby excluding genetic variations when comparing the results. Plasma and urine were collected during and after the drug infusion, and the drug concentrations were measured by means of a sensitive fluorimetric procedure. The study shows that one obtains: 1. a much higher plasma concentration of adriamycin when it is given in the complexed form. 2. a lower urine excretion of adriamycin and fluorescent metabolites when adriamycin is administered as the DNA-complex.
No takes yet. Share an insight, caveat, or question.
Kummen et al. (1978) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: